可溶性细胞间粘附分子-1放射免疫分析法  

The establishment of RIA method for the assessment of soluble intracellular adhesion molecule-1 and its clinical application

作　　者：张志友[1] 方佩华[1] 吕枚[1] 高硕[1] 

机构地区：[1]天津医科大学总医院核医学科,300052

出　　处：《中华核医学杂志》2002年第4期237-240,共4页Chinese Journal of Nuclear Medicine

摘　　要：目的　建立血清可溶性细胞间粘附分子 1(sICAM 1)放射免疫分析法 (RIA)并用于Gra ves病 (GD)的临床检测。方法　用sICAM 1免疫家兔 ,制备多抗 ,建立sICAM 1RIA法。测定对照组4 0 0例 ,治疗前GD患者 312例 ,抗甲状腺药物治疗后甲状腺功能 (简称甲功 )恢复正常的GD患者 4 4 5例 ,单纯性甲状腺肿大患者 5 6例 ,1 31 I治疗前后 36例 ,抗甲状腺药物治疗前后 93例 ,甲状腺次全切除前后GD患者 6例 ,GD停药复发患者 5 2例的血清sICAM 1。结果　sICAM 1RIA灵敏度为 6 6 5 3μg L ;特异性 :非特异结合 <8% ;精密度 :批内低、中、高值变异分别为 4 2 5 %、4 35 %、3 99% (n =6 ) ,批间变异分别为 5 5 5 %、2 82 %、3 4 8% (n =6 ) ;准确性 :回收率平均为 10 0 88%。sICAM 1正常值范围 ( x± 2s) :(16 8 4 3± 72 4 6 ) μg L。治疗前GD组、抗甲状腺药物治疗后甲功恢复正常的GD组血清sICAM 1均明显高于对照组 (P <0 0 1) ,单纯性甲状腺肿大患者组与对照组差异无显著性 (P >0 0 5 ) ;治疗前GD组明显高于抗甲状腺药物治疗后甲功恢复正常的GD组 (P <0 0 5 ) ;GD患者在甲状腺次全切除后、1 31 I及抗甲状腺药物治疗后血清sICAM 1均明显低于治疗前 (P <0 0 5 ) ;GD停药复发患者组血清sICAMObjective To establish the radioimmunoassay (RIA) method for the assessment of soluble intracellular adhesion molecule 1 (sICAM 1) and to apply it in clinical evaluation of Graves' disease (GD) Methods The rabbits were immunized by sICAM 1 to prepare the specific polyclonal antibody for the sICAM 1 RIA The study population was composed of 400 healthy people, 56 simple goiter patients, 312 GD patients before treatment, 445 GD patients after treatment with antithyroid drug whose thyroid functional parameters were normal, 36 GD patients before and after 131 I treatment, 93 GD patients before and after antithyroid drug treatment, 6 GD patients before and after thyroidectomy, 52 relapse GD patients and their serum sICAM 1 levels were measured Results The sensitivity of sICAM 1 RIA was 66 53 μg/L The non specific binding was less than 8% The intra assay coefficients of variation ( CV ) were 4 25%, 4 35%, 3 99% ( n =6) and the inter assay CV were 5 55%, 2 82%, 3 48% ( n =6) for 110, 220, 320 μg/L, respectively The average recovery rate of the method was 100 88% The serum level of sICAM 1 ( μg/L) in normal group was 168 43±72 46( ±2s )and in the GD groups of before and after antithyroid drug treatment the serum levels were both higher than that in normal groups( P< 0 01); in the simple goiter group, no significant difference was seen compared with normal group( P >0 05); in the before treatment GD group it was higher than that in after treatment group ( P< 0 05); in the before thyroidectomy, 131 I treatment and antithyroid drug treatment GD groups, the levels were all decreased markedly after treatment ( P< 0 05); in the relapse GD group, it was higher than in the GD group with normal thyroid functional parameters ( P< 0 01) Conclusions sICAM 1 RIA has been established successfully The results show that sICAM 1 may be an important indicator for estimating effects of therapy, the relapse of GD and the necessity of drug administration ce

关 键 词：可溶性细胞间粘附分子-1 放射免疫分析法 格雷夫斯病 血清 

分 类 号：R817[医药卫生—影像医学与核医学]